Next Article in Journal
Current Therapeutic Strategies and Novel Approaches in Osteosarcoma
Previous Article in Journal
99mTc-HYNIC-Annexin A5 in Oncology: Evaluating Efficacy of Anti-Cancer Therapies
Previous Article in Special Issue
The Lack of Predictors for Rapid Progression in Prostate Cancer Patients Receiving Sipuleucel-T
Open AccessReview

Immunotherapy and Immune Evasion in Prostate Cancer

1
Department of Oncology, Wayne State University, Detroit, MI 48201, USA
2
Department of Medicine, Wayne State University, Detroit, MI 48201, USA
3
Department of Immunology and Microbiology, Wayne State University, Detroit, MI 48201, USA
*
Authors to whom correspondence should be addressed.
Cancers 2013, 5(2), 569-590; https://doi.org/10.3390/cancers5020569
Received: 29 March 2013 / Revised: 16 April 2013 / Accepted: 8 May 2013 / Published: 24 May 2013
(This article belongs to the Special Issue Immune Responses to Human Prostate Cancer)
Metastatic prostate cancer remains to this day a terminal disease. Prostatectomy and radiotherapy are effective for organ-confined diseases, but treatment for locally advanced and metastatic cancer remains challenging. Although advanced prostate cancers treated with androgen deprivation therapy achieves debulking of disease, responses are transient with subsequent development of castration-resistant and metastatic disease. Since prostate cancer is typically a slowly progressing disease, use of immune-based therapies offers an advantage to target advanced tumors and to induce antitumor immunity. This review will discuss the clinical merits of various vaccines and immunotherapies in castrate resistant prostate cancer and challenges to this evolving field of immune-based therapies. View Full-Text
Keywords: prostate cancer; immunotherapy; vaccine; castrate resistant prostate cancer; bispecific antibody prostate cancer; immunotherapy; vaccine; castrate resistant prostate cancer; bispecific antibody
Show Figures

Figure 1

MDPI and ACS Style

Thakur, A.; Vaishampayan, U.; Lum, L.G. Immunotherapy and Immune Evasion in Prostate Cancer. Cancers 2013, 5, 569-590.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop